Antibody Drug Conjugates Market Size 2024 : Opportunity Analysis and Industry Forecast 2030

Antibody drug conjugates are highly powerful biopharmaceutical medications prepared by integrating two principles i.e. a cell killing highly powerful active pharmaceutical ingredient (HPAPI) and explicit nature of monoclonal antibodies. They are highly effective anticancer drugs targeting only cancer infected cells thus, leaving healthy uninfected cell intact facilitating quick recovery of cancer patients.

Some of the key players involved in the Market are:

• F. Hoffmann-La Roche Ltd. - Holding a 36.24% market share, Roche leads with products like Kadcyla (ado-trastuzumab emtansine) and Polivy (polatuzumab vedotin), both of which have shown significant revenue growth .
• Daiichi Sankyo Company, Limited - With a 25.59% market share, Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has seen its revenue double in 2022 compared to 2021, reflecting its strong market position .
• Seagen Inc. - Acquired by Pfizer, Seagen holds a 17.97% market share and is known for its flagship product Adcetris (brentuximab vedotin), used in treating various lymphomas.
• Gilead Sciences Inc. - Holding an 8.86% market share, Gilead expanded its oncology portfolio by acquiring Immunomedics, the maker of Trodelvy (sacituzumab govitecan) .
• Genmab - With a 3% market share, Genmab collaborates on ADC development, including partnerships with companies like Seagen .
• Pfizer Inc. - Post-acquisition of Seagen, Pfizer holds a 2.85% market share and aims to generate $10 billion annually from ADCs by 2030 .
• GlaxoSmithKline plc (GSK) - With a 1.62% market share, GSK is investing in ADCs, including discussions to acquire biotech firms specializing in cancer drugs .
• ADC Therapeutics SA - Holding a 1.37% market share, this Swiss company focuses exclusively on ADC development .
• AstraZeneca plc - With a 1.03% market share, AstraZeneca is investing in ADC manufacturing facilities and aims to launch 20 new medicines by 2030 .
• RemeGen - A Chinese biopharmaceutical company holding a 0.74% market share, contributing to the global ADC landscape .

Get Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) Click Here: https://www.alliedmarketresearch.com/request-sample/1467

What are the Driving Factors Of Antibody Drug Conjugates (ADCs) Market?

The growth of global AI in healthcare market is mainly driven by rise in the volume of healthcare data and increase in complications of datasets. This leads to increase in the need for AI in healthcare in the market. The impact of the COVID-19 has positively impacted the growth of various healthcare-related sectors, one of which is AI in healthcare.

Antibody Drug Conjugates (ADCs) Market Segmentation can be done based on several factors, including:

The Antibody Drug Conjugates (ADCs) market can be segmented based on various factors. Here are some common segmentation approaches:

By Type of Cancer: ADCs are designed to target specific types of cancer cells. The market can be segmented based on the type of cancer that ADCs are developed to treat, such as breast cancer, lung cancer, lymphoma, leukemia, ovarian cancer, and others.

By Component: ADCs consist of three main components: the monoclonal antibody, the cytotoxic payload, and the linker that connects them. The market can be segmented based on these components, focusing on the different types of antibodies, payloads, and linkers used in ADC development.

By Target Antigen: ADCs are designed to bind to specific antigens present on cancer cells. The market can be segmented based on the target antigen, such as HER2 (human epidermal growth factor receptor 2), CD30, CD33, CD22, and others.

By Stage of Development: ADCs can be in different stages of development, ranging from early-stage research and preclinical studies to clinical trials and approved products. The market can be segmented based on the stage of development to differentiate between ADCs in the pipeline and those already commercialized.

By Region: The ADC market can also be segmented geographically, considering regional markets such as North America, Europe, Asia-Pacific, and the rest of the world. This segmentation helps understand the regional demand, regulatory landscape, and market dynamics for ADCs.

By End User: The market can be segmented based on the end users of ADCs, including hospitals, specialty clinics, research institutes, and pharmaceutical companies.

Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/1467

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Which are the driving factors responsible for the growth of market?
Which are the roadblock factors of this market?
What are the new opportunities, by which market will grow in coming years?
What are the trends of this market?
Which are main factors responsible for new product launch?
How big is the global & regional market in terms of revenue, sales and production?
How far will the market grow in forecast period in terms of revenue, sales and production?
Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
Which region has more opportunities?

Region Analysis

North America
(U.S., Canada, Mexico)
Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.